pmedpharmФармация и фармакологияPharmacy & Pharmacology2307-92662413-2241Pyatigorsk Medical and Pharmaceutical Institute - branch of Volgograd State Medical Univer10.19163/2307-9266-2018-6-5-402-418pmedpharm-323Research ArticleОБЗОРЫ, ЛЕКЦИИREVIEWS, LECTURESОБЗОР КЛИНИЧЕСКИХ ИССЛЕДОВАНИЙ ПРОТИВОРАКОВОЙ АКТИВНОСТИ ПРОИЗВОДНЫХ АРТЕМИЗИНИНАA REVIEW OF CLINICAL STUDIES OF ANTICANCER ACTIVITY OF ARTEMISININ DERIVATIVEKоноваловД. А.KonovalovD. A.

Дмитрий Алексеевич Коновалов – доктор фармацевтических наук, профессор, заместитель директора по научной работе

Konovalov  Dmitry  Alexeevich –  Doctor  of  Pharmaceutical Sciences, Professor

Pyatigorsk

d.a.konovalov@pmedpharm.ruХамилоновА. А.KhamilonovA. A.

Артур Александрович Хамилонов – аспирант кафедры фармакогнозии

Khamilonov Artur Aleksandrovich– postgraduate student of the Chair of Pharmacognosy

Pyatigorsk

spartan400@yandex.ruШевчукО. М.ShevchukO. M.

Оксана Михайловна Шевчук – доктор биологических наук, заведующий лабораторией ароматических и лекарственных растений

пгт. Никита, Республика Крым

Shevchuk Oksana Mikhailovna – Doctor of Biological Sciences, Head of the Laboratory of Aromatic and Medicina Plants

Nikita, Republic of Crimea

oksana_shevchuk1970@mail.ruЛогвиненкоЛ. А.LogvinenkoL. A.

Логвиненко Лидия Алексеевна – научный сотрудник лаборатории ароматических и лекарственных растений 

пгт. Никита, Республика Крым

Logvinenko Lidiya Alekseevna – scientific worker of the laboratory of aromatic medicinal plants

Nikita, Republic of Crimea

Пятигорский медико-фармацевтический институт – филиал ВолгГМУ Минздрава РоссииРоссияPyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University of the Ministry of Health of RussiaRussian FederationФедеральное государственное бюджетное учреждение науки «Ордена Трудового Красного Знамени Никитский ботанический сад – Национальный научный центр РАН»РоссияNikitsky Botanic GardenRussian Federation20181011201865402418Copyright © Kоновалов Д.А., Хамилонов А.А., Шевчук О.М., Логвиненко Л.А., 20182018Kоновалов Д.А., Хамилонов А.А., Шевчук О.М., Логвиненко Л.А.Konovalov D.A., Khamilonov A.A., Shevchuk O.M., Logvinenko L.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmpharm.ru/jour/article/view/323

Артемизинин – сесквитерпеновый лактон, выделенный из надземной части полыни однолетней (Artemisia annua L.) в 70-х годах XX века. На основе его производных созданы и широко используются самые эффективные лекарственные средства для лечения малярии. За последние два десятилетия проведены многочисленные in vitro и in vivo исследования, показавшие противораковую активность этих препаратов в отношении некоторых линий раковых клеток. Целью исследования являлся обзор научной информации по изучению клинических случаев и результатов осуществлённых клинических испытаний с использованием лекарственных средств на основе производных артемизинина. Материалы и методы. Исследование проводилось с использованием информационно-поисковых (PubMed, ScholarGoogle,) и библиотечных баз данных (eLibrary, Cyberleninca), а также приложения ResearchGate для семантического поиска. Результаты и обсуждение. Установлено, что наибольшее количество известных клинических случаев и выполненных клинических исследований связано с изучением противораковой активности одного из производных артемизинина – артесуната. Данные, полученные различными исследовательскими группами пока не позволяют говорить о ярко выраженной активности последнего. Однако установлены факты продления жизни больных, улучшения её качества, повышения контроля над заболеванием. Заключение. Опубликованные данные клинических случаев и клинических исследований, проведённых за период с 2001 г. по 2016 г., вселяют сдержанный оптимизм по поводу перспективы использования препаратов на основе некоторых производных артемизинина в онкологии.

Artemisinin is a sesquiterpene lactone isolated from the aerial part of sweet wormwood (Artemisia annua L.) in the 1970s. Based on its derivatives, the most effective medicines for the treatment of malaria have been created and are widely used. Over the past two decades, numerous in vitro and in vivo studies have been performed. They have shown the anticancer activity of these drugs in relation to certain cancer cell lines. The aim of the study is the review the scientific information on the clinical cases and the results of clinical trials carried out using drugs based on artemisinin derivatives. Material and methods. The study was conducted with the use of information search (PubMed, ScholarGoogle,) and library databases (Cochrane, eLibrary, Cyberleninca), as well as ResearchGate application for semantic search. Results and discussion. It has been established that the largest number of known clinical cases and completed clinical studies is associated with the study of the anticancer activity of one of the artemisinin derivatives - artesunate. The data obtained by various research groups do not yet allow us to speak of a pronounced activity of the latter. However, the facts of prolonging the life of patients, improving its quality, increasing control over the disease have been established. Conclusion. The published data of clinical cases and clinical studies performed for the period from 2001 to 2016, instill restrained optimism about the prospect of using drugs based on some artemisinin derivatives in oncology.

сесквитерпеновые лактоныартемизининартесунатартеэтерартеметерраковые заболеванияsesquiterpene lactonesartemisininartesunatearteetherartemethercancersReferencesCancer – World Health Organization // WHO media centre: cancer, fact sheet, 12 September 2018. Режим доступа: http://www.who.int/mediacentre/factsheets/fs297/en/. (accessed: 03.08.2018).Cancer – World Health Organization. WHO media centre: cancer, fact sheet, 12 September 2018 Available at: http://www.who.int/mediacentre/factsheets/fs297/en/. (accessed 03.08.2018).Newman D.J., Cragg G.M. Natural products as sources of new drugs from 1981 to 2014 // J. Nat. Prod. – 2016. – Vol. 79. – P. 629–661. DOI: 10.1021/acs.jnatprod.5b01055.Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 2016; 79:629–61. DOI: 10.1021/acs.jnatprod.5b01055.Kinghorn A.D., de Blanco E.J.C., Lucas D.M., Rakotondraibe H.L., Orjala J., Soejarto D.D., Oberlies N.H., Pearce C.J., Wani M.C., Stockwell B.R., Burdette J.E., Swanson S.M., Fuchs J.R., Phelps M.A., Xu L., Zhang X., Shen Y.Y. Discovery of Anticancer Agents of Diverse Natural Origin // Anticancer Res. – 2016. – Vol. 36, №11. – P. 5623–5637. DOI: 10.21873/anticanres.11146.Kinghorn AD, de Blanco E.C, Lucas DM, Rakotondraibe HL, Orjala J, Soejarto DD, Oberlies NH, Pearce CJ, Wani MC, Stockwell BR, Burdette JE, Swanson SM, Fuchs JR, Phelps MA, Xu L, Zhang X, Shen YY. Discovery of Anticancer Agents of Diverse Natural Origin. Anticancer Res. 2016; 36(11):5623–37. DOI: 10.21873/anticanres.11146.Tariq A., Sadia S., Pan K., Ullah I., Mussarat S., Sun F., Xiong Q. A systematic review on ethnomedicines of anticancer plants // Phytotherapy Research. – 2017. – Vol. 31, № 2. – P. 202–264. DOI: 10.1002/ptr.575.Tariq A, Sadia S, Pan K, Ullah I, Mussarat S, Sun F, Xiong Q. A systematic review on ethnomedicines of anticancer plants. Phytotherapy Research. 2017; 31(20):202–264. DOI: 10.1002/ptr.5751.Akhtar M.S., Swamy M.K. Anticancer Plants: Clinical Trials and Nanotechnology. 2018.Akhtar MS, Swamy MK. Anticancer Plants: Clinical Trials and Nanotechnology. 2018.Akhtar M.S., Swamy M.K. Anticancer Plants: Natural Products and Biotechnological Implements. 2018.Akhtar MS, Swamy MK. Anticancer Plants: Natural Products and Biotechnological Implements. 2018.Butler M.S., Robinson A.A.B., Cooper M.A. Natural product and natural product derived drugs in clinical trials // Nat. Prod. Rep. – 2014. – Vol. 31, №11. – P. 1612–1661. DOI: 10.1039/c4np00064a.Butler MS, Robinson AAB, Cooper MA. Natural product and natural product derived drugs in clinical trials. Nat. Prod. Rep. 2014; 31:1612–61. DOI: 10.1039/c4np00064a.Crespo-Ortiz M.P., Wei M.Q. Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug // Journal of Biomedicine and Biotechnology. – 2012. – Vol. 2012, – Р. 18. DOI:10.1155/2012/247597.Crespo-Ortiz MP, Wei MQ. Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug. Journal of Biomedicine and Biotechnology. 2012; 2012, Article ID 247597, 18 p. DOI:10.1155/2012/247597.Efferth Th. Artemisinin – Second Career as Anticancer Drug? // World J. Tradit. Chin. Med. – 2015. – Vol. 1, №4. – P. 2–25. DOI: 10.1016/j.tips.2008.07.004.Efferth Th. Artemisinin – Second Career as Anticancer Drug? World J Tradit Chin Med 2015; 1(4): 2–25. DOI: 10.1016/j.tips.2008.07.004.Ren Y., Yu J., Kinghorn A.D. Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones // Current Medicinal Chemistry. – 2016. – Vol. 23, № 23. – P. 2397–2420.Ren Y, Yu J, Kinghorn AD. Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones.Curr Med Chem. 2016; 23(23):2397–420.Bhaw-Luximon A., Jhurry D. Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives // Cancer chemotherapy and pharmacology. – 2017. – Vol. 79, № 3. – P. 451–466. DOI: 10.1007/s00280-017-3251-7.Bhaw-Luximon A, Jhurry D. Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives. Cancer Chemother Pharmacol. 2017 Mar; 79(3):451–66. DOI: 10.1007/s00280-017-3251-7.Efferth T. Cancer combination therapies with artemisinin-type drugs // Biochemical pharmacology. – 2017. – Vol.139. – P. 56–70. DOI: 10.1016/j.bcp.2017.03.019.Efferth T. Cancer combination therapies with artemisinin-type drugs. Biochem Pharmacol. 2017 Sep 1; 139:56– 70. DOI: 10.1016/j.bcp.2017.03.019.Konstat-Korzenny E., Ascencio-Aragón J., Niezen-Lugo S., Vázquez-López R. Artemisinin and its synthetic derivatives as a possible therapy for cancer // Medical Sciences. – 2018. – Vol. 6, – №1. – P. 19–28. DOI: 10.3390/medsci6010019.Konstat-Korzenny E., Ascencio-Aragón J, Niezen-Lugo S, Vázquez-López R. Artemisinin and its synthetic derivatives as a possible therapy for cancer. Medical Sciences. 2018; 6(1):19–28. DOI: 10.3390/medsci6010019.Abba M.L., Patil N., Leupold J.H., Saeed M.E., Efferth T., Allgayer H. Prevention of carcinogenesis and metastasis by Artemisinin-type drugs // Cancer letters. – 2018. – Vol. 429. – P. 11-18. DOI: 10.1016/j.canlet.2018.05.008.Abba ML, Patil N, Leupold JH, Saeed ME, Efferth T, Allgayer H. Prevention of carcinogenesis and metastasis by Artemisinin-type drugs. Cancer Lett. 2018 Aug 10; 429:11–18. DOI: 10.1016/j.canlet.2018.05.008.O’Neill P.M., Barton V.E., Ward St.A. The Molecular Mechanism of Action of Artemisinin. The Debate Continues // Molecules. – 2010. – Vol. 15. – P. 1705–1721. DOI: 10.3390/molecules15031705.O’Neill PM, Barton VE, Ward StA. The Molecular Mechanism of Action of Artemisinin – The Debate Continues. Molecules. 2010 Mar 12;15(3):1705–21. DOI: 10.3390/molecules15031705.Wong Y.K., Xu C., Kalesh K.A., He Y., Lin Q., Wong W.F., Wang, J. Artemisinin as an anticancer drug: recent advances in target profiling and mechanisms of action // Medicinal research reviews. – 2017. – Vol. 37, № 6. – P. 1492–1517. DOI: 10.4103/2141-9248.153609.Wong YK, Xu C, Kalesh KA, He Y, Lin Q, Wong WF, Wang J. Artemisinin as an anticancer drug: recent advances in target profiling and mechanisms of action. Medicinal research reviews. 2017 Nov; 37(6):1492-517. DOI: 10.4103/2141–9248.153609.Tu Y. From Artemisia Annua L. to Artemisinins: The Discovery and Development of Artemisinins and Antimalarial Agents. – Academic Press, Cambridge 2017. 468 pp. DOI: 10.1002/cmdc.201700632.Tu Y. From Artemisia Annua L. to Artemisinins: The Discovery and Development of Artemisinins and Antimalarial Agents. Academic Press, 2017; 13(1):468. DOI: 10.1002/cmdc.201700632.Nakase I., Lai H., Singh N.P., Sasaki T. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation // International Journal of Pharmaceutics. – 2008 Apr 16; – Vol. 354. №1–2. – P. 28–33.Nakase I, Lai H, Singh NP, Sasaki T. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. International Journal of Pharmaceutics. 2008 Apr 16; 354(1-2):28-33. DOI: 10.1016/j.ijpharm.2007.09.003.Li Q, Weina PJ, Milhous WK. Pharmacokinetic and pharmacodynamic profiles of rapidacting artemisinins in the antimalarial therapy // Curr Drug Ther. – 2007. – Vol. 2, № 3. – Р. 210–223. DOI: 10.2174/157488507781695649.Li Q, Weina PJ, Milhous WK. Pharmacokinetic and pharmacodynamic profiles of rapidacting artemisinins in the antimalarial therapy. Curr Drug Ther. 2007; 2(3):210–23. DOI: 10.2174/157488507781695649.Aftab T., Ferreira J.F.S., Khan M.M.A., Naeem M. Artemisia annua – Pharmacology and Biotechnology. Springer Verlag Berlin Heidelberg. 2014.Aftab T, Ferreira JFS, Khan MMA, Naeem M. Artemisia annua – Pharmacology and Biotechnology. – Springer-Verlag Berlin Heidelberg 2014.Belafsky P.C. Laryngeal Cancer. San Diego Center for Voice and Swallowing Disorders. Режим доступа: http://www.sandiegovoice.org/larynxca.html.Belafsky PC. Laryngeal Cancer. San Diego Center for Voice and Swallowing Disorders. Available from: http://www.sandiegovoice.org/larynxca.html.Singh N.P., Verma K.B. Case report of a laryngeal squamous cell carcinoma treated with artesunate. // Arch Oncol. – 2002. – Vol.10, – №4. – P.279–280.Singh NP, Verma KB. Case report of a laryngeal squamous cell carcinoma treated with artesunate. Arch Oncol 2002; 10(4):279–80.Siegel R.L., Miller K.D., Jemal A. Cancer Statistics // CA Cancer J Clin. – 2018 Jan; – Vol. 68, №1 – Р. 7–30. DOI: 10.3322/caac.21332.Siegel RL, Miller KD, Jemal A. Cancer Statistics. CA Cancer J Clin. 2016; 66:7–30. DOI: 10.3322/caac.21332.Berger T.G., Dieckmann D., Efferth T., Schultz E.S., Funk J.O., Baur A., Schuler G. Artesunate in the treatment of metastatic uveal melanoma – first experiences. // Oncol Rep. – 2005. – Vol. 14, № 6. – Р. 1599–1603.Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A, Schuler G. Artesunate in the treatment of metastatic uveal melanoma – first experiences. Oncol Rep.2005; 14(6):1599–1603.Singh N.P., Panwar V.K. Case report of a pituitary macroadenoma treated with artemether. Integr Cancer Ther. – 2006. – Vol. 5, № 4. – Р. 391–394.Singh NP, Panwar VK. Case report of a pituitary macroadenoma treated with artemether. Integrative cancer therapies. 2006; 5(4):391–394. DOI: https://doi.org/10.1177/1534735406295311.Zhang Z.Y., Yu S.Q., Miao L.Y., Huang X.Y., Zhang X.P., Zhu Y.P., Xia X.H., Li D.Q. Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: A randomized controlled trial // J Chin Integr Med / Zhong Xi Yi Jie He Xue Bao. – 2008. – Vol. 6, № 2. – Р. 134–138.Zhang ZY, Yu SQ, Miao LY, Huang XY, Zhang XP, Zhu YP, Xia XH, Li DQ. Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: A randomized controlled trial. J Chin Integr Med / Zhong Xi Yi Jie He Xue Bao. 2008; 6(2): 134–138.Efferth T, Dunstan H, Sauerbrey A, Miyachi H and Chitambar CR. The anti-malarial artesunate is also active against cancer. // Int J. Oncol. – 2001. – Vol. 18, №4. – P. 767–773.Efferth T, Dunstan H, Sauerbrey A, Miyachi H and Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol. 2001 Apr; 18(4):767–73.Jansen F.H., Adoubi I., KC J.C., Cnodder D.E.T., Jansen N., Tschulakow A., Efferth T. First study of oral Artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers. Anticancer Res. – 2011. – Vol. 31, № 12, – Р. 4417–4422.Jansen FH, Adoubi I, KC JC, Cnodder DET, Jansen N, Tschulakow A, Efferth T. First study of oral Artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers. Anticancer Res. 2011 Dec; 31(12):4417–22.GLOBOCAN (2012). Estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer; World Health Organization (WHO).GLOBOCAN (2012). Estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer; World Health Organization (WHO).Mao H., Gu H., Qu X., Sun J., Song B., Gao W., Liu J., Shao Q. Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro // Int. J. Mol. Med. – 2013. – Vol. 31, № 1, – P. 213–218. DOI: 10.3892/ijmm.2012.1176.Mao H, Gu H, Qu X, Sun J, Song B, Gao W, Liu J, Shao Q. Involvement of the mitochondrial pathway and Bim/ Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro. Int. J. Mol. Med. 2013; 31(1):213–218. DOI: 10.3892/ijmm.2012.1176Ericsson Th., Blank A., von Hagens C., Ashton M., Äbelö A. Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer // Eur. J. Clin. Pharmacol. – 2014. – Vol. 70. P. 1453–1463. DOI: 10.1007/s00228-014-1754-2.Ericsson Th, Blank A, von Hagens C, Ashton M, Äbelö A. Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer.Eur. J. Clin. Pharmacol. 2014; 70(12):1453–63. DOI: 10.1007/s00228-014-1754-2.König M., von Hagens C., Hoth S., Baumann I., Walter-Sack I., Edler L., Sertel S. Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study // Cancer Chemother Pharmacol. – 2016. – Vol. 77, №2. – P. 413–427. DOI: 10.1007/s00280-016-2960-7.König M, von Hagens C, Hoth S, Baumann I, Walter-Sack I, Edler L, Sertel S. Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study. Cancer Chemother Pharmacol. 2016; 77(2):413–27. DOI: 10.1007/s00280-016-2960-7.Hagens C., Walter-Sack I., Goeckenjan M., Osburg J., Storch-Hagenlocher B., Sertel S., Efferth T. Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2). Breast cancer research and treatment. – 2017. – Vol. 164, № 2, – Р. 359–369. DOI: 10.1007/s10549-017-4261-1.Hagens C, Walter-Sack I, Goeckenjan M, Osburg J, Storch-Hagenlocher B, Sertel S, Efferth T (2017). Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2). Breast Cancer Res Treat. 2017 Jul; 164(2):359–69. DOI: 10.1007/s10549-017-4261-1.Michaelsen Fr.W., Saeed M.E.M., Schwarzkopf J., Efferth Th. Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma // Phytomedicine. – 2015. Dec 15; – Vol. 22, №14. – Р. 1223–31. DOI: 10.1016/j.phymed.2015.11.001.Michaelsen FrW, Saeed MEM, Schwarzkopf J, Efferth Th. Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma. Phytomedicine. 2015 Dec 15; 22(14):1223–31. DOI: 10.1016/j.phymed.2015.11.001.Krishna S., Ganapathi S., Ster I.C., Saeed M.E., Cowan M., Finlayson C., Kovacsevics H., Jansen H., Kremsner P.G., Efferth T., Kumar D. A randomised, double blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer // EBioMed. – 2015 Jan; – Vol. 2, №1. – Р. 82–90. DOI: 10.1016/j.ebiom.2014.11.010.Krishna S, Ganapathi S, Ster IC, Saeed ME, Cowan M, Finlayson C, Kovacsevics H, Jansen H, Kremsner PG, Efferth T, Kumar D. A randomised, double blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer. EBioMedicine. 2015 Nov 15; 2(1):82–90. DOI: 10.1016/j.ebiom.2014.11.010.Deeken J.F., Wang H., Hartley M., Cheema A.K., Smaglo B., Hwang, J.J., Liu S. (2018). A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies // Cancer chemotherapy and pharmacology. – 2018. – Vol. 81, № 3. – Р. 587–596.Deeken JF, Wang H, Hartley M, Cheema AK, Smaglo B, Hwang JJ, Liu S. (2018). A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol. 2018 Mar; 81(3):587–596. DOI: 10.1007/s00280-018-3533-8.

The authors declare that there are no conflicts of interest present.